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Background: since 1999 data from pulmonary
hypertension (PH) patients from all PH centres
in Switzerland were prospectively collected. We
analyse the epidemiological aspects of these data. 
Methods: PH was defined as a mean pul-
monary artery pressure of >25 mm Hg at rest or
>30 mm Hg during exercise. Patients with pul-
monary arterial hypertension (PAH), PH associ-
ated with lung diseases, PH due to chronic
thrombotic and/or embolic disease (CTEPH), or
PH due to miscellaneous disorders were regis-
tered. Data from adult patients included between
January 1999 and December 2004 were analysed. 
Results: 250 patients were registered (age 58 ±
16 years, 104 (41%) males). 152 patients (61%)
had PAH, 73 (29%) had CTEPH and 18 (7%)
had PH associated with lung disease. Patients 
<50 years (32%) were more likely to have PAH
than patients >50 years (76% vs. 53%, p <0.005).
Twenty-four patients (10%) were lost to follow-
up, 58 patients (26%) died and 150 (66%) sur-
vived without transplantation or thrombend -
arterectomy. Survivors differed from patients 
who died in the baseline six-minute walking dis-
tance (400 m [300–459] vs. 273m [174–415]), the
functional impairment (NYHA class III/IV 86%
vs. 98%), mixed venous saturation (63% [57–68]
vs. 56% [50–61]) and right atrial pressure (7 mm
Hg [4–11] vs. 11 mm Hg [4–18]). 
Discussion: PH is a disease affecting adults of
all ages. The management of these patients in
specialised centres guarantees a high quality of
care. Analysis of the registry data could be an in-
strument for quality control and might help iden-
tify weak points in assessment and treatment of
these patients.
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Summary
Pulmonary hypertension (PH) is a devastat-
ing disease leading to right heart failure and
death. In the last 15 years, a better understanding
of pathogenesis and risk factors has led to new di-
agnostic and therapeutic approaches and hence to
an increased interest in detection of this incurable
disease [1–3]. Since PH is a rare disease, informa-
tion about epidemiology, follow-up and prognosis
are difficult to obtain, but are invaluable to im-
prove therapy and assess outcome parameters [4].
The Swiss Registry for Pulmonary Hypertension
was initiated in 1999 with the aim to gain more
insight into prevalence, epidemiology, therapy
and outcome of patients with pulmonary hyper-
tension in Switzerland. First retrospective data
have been published in 2001 [5]. Since then, data
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Abbreviations
CTEPH chronic thrombotic/embolic pulmonary hypertension
IPAH idiopathic pulmonary arterial hypertension
NYHA New York Heart Association
6MWD 6 minute walking distance
PAH pulmonary arterial hypertension
PAPmean mean pulmonary artery pressure
PH pulmonary hypertension
TEA thrombendarterectomy
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from PH patients from all PH centres and associ-
ated hospitals in Switzerland were prospectively
collected. In this study, we analyse the epidemio-
logical aspects of these data and focus on basic
clinical characteristics of PH patients and esti-
mated burden of the disease in the population.
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Methods
Prospective data collection took place in 5 Univer-
sity Hospitals (Basel, Bern, Geneva, Lausanne, Zurich)
and in 4 associated hospitals (Aarau, Barmelweid, Lo-
carno, St Gallen) in Switzerland. Patients with pulmonary
arterial hypertension (idiopathic, associated with collagen
vascular disease, portal hypertension, HIV infection,
drugs or toxins), PH associated with lung diseases and/or
hypoxaemia, PH due to chronic thrombotic and/or
 embolic disease, or PH due to miscellaneous disorders
(sarcoidosis, histiocytosis X, lymphangiomyomatosis,
compression of pulmonary vessels) were included in the
registry. Patients with PH due to left heart disease were
not included as well as three patients with pulmonary an-
giosarcoma. Due to a change in nomenclature in 2004,
the term “idiopathic pulmonary arterial hypertension”
(IPAH) includes both sporadic and familial cases of pul-
monary arterial hypertension (PAH).
Pulmonary hypertension was defined as a mean pul-
monary artery pressure of >25 mm Hg at rest or >30 mm
Hg on exercise.
The following data were collected: age and gender of
the patient, diagnosis according to the Evian clinical clas-
sification [6], date of diagnosis, height, weight, vital signs
(blood pressure, heart rate and oxygen saturation at rest),
NYHA class, six minute walking distance (6MWD),
haemodynamics assessed by right heart catheterisation
(systolic pulmonary artery pressure, mean pulmonary ar-
tery pressure (PAPmean), right atrial pressure, cardiac
output, mixed venous oxygen saturation, pulmonary vas-
cular resistance, response to vasoreactivity testing, tricus-
pid pressure gradient measured with transthoracic
Doppler echocardiography, liver enzymes, creatinine, co-
agulation studies (INR) and current medication (diuret-
ics, anticoagulation, calcium antagonists, iloprost, bosen-
tan, sildenafil, oxygen). A positive response to vasoreactiv-
ity testing was defined as a decrease of PAPmean of more
than 10 mm Hg, to a value lower than 40 mm Hg, with a
normal or high cardiac output [7]. The tricuspid pressure
gradient was calculated from the maximal transtricuspid
jet in Doppler echocardiography using the modified
Bernoulli equation. 
Whether a patient was included in the registry or not
was at discretion of the treating PH specialist. When a
patient was included in the registry, data collection
started at the first visit of the patient in the PH centre or
associated hospital, and continued every 3 to 6 months
until occurrence of one of the clinical endpoints (death,
lung transplantation, pulmonary thrombendarterectomy).
The clinical follow-up of the patients was performed as
usual irrespective of whether a patient was included in the
registry or not.
In this study, we analyse data from adult patients 
(>18 years of age) that were included in the registry be-
tween January 1999 and December 2004 (table 1). 
Statistics: in descriptive analyses we report median
[interquartile range] for continuous parameters and for
categorical parameters frequency distribution. 
For estimation of prevalence and incidence of PH in
Switzerland we assumed an adult population of 6 million
inhabitants [8]. The prevalence of PH for the year 2004
was calculated by dividing the number of patients diag-
nosed with PH and included in the registry before 2004,
and known to be alive in 2004, by the approximate num-
ber of adult Swiss inhabitants. Incidence estimates were
calculated for each year by dividing the number of pa-
tients diagnosed with PH and included in the registry
each year by the approximate number of adult Swiss in-
habitants (6 million).
For survival analyses, follow-up time was calculated
from date of registration in the registry until last clinical
visit or the date of death. Differences between the two
outcome groups (survivors and non-survivors) were de-
scribed by presenting Kaplan-Meier survival curves for
selected variables. Analysis was performed with  STATA
9.1 software (Stata Corp LP, Texas, USA).  
Ethics: written informed consent was obtained from
each patient before inclusion in the registry. 
1999 2000 2001 2002 2003 2004 total
Number of patients included 15 36 30 47 63 59 250
Lost of follow-up 2 4 0 4 4 10 24
Number of patients included in the registry each year
Table 1
Results
A total of 252 adult patients were included in
the registry between January 1999 and December
2004. Two patients with PH due to left heart disease
were mistakenly included in the registry, and were
excluded from further analysis. Median follow-up of
the remaining 250 patients was 18.8 [9–31] months.
Median time between successive visits was 3 [2–5]
months. There were more female (147; 59%) than
male patients. Median age was 59 [46–70] years for
female patients, and 63 [45–70] years for male pa-
tients. Most patients (90%) had either PAH or
chronic thrombotic/embolic pulmonary hyperten-
sion (CTEPH). Further information about baseline
characteristics of patients and aetiology is given in
table 2. About one third (32%) of patients were
younger than 50 years. Of these, 76% had PAH,
whereas only 53% of patients over 50 years of age
had PAH. Age distribution is shown in figure 1.
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Seventy-one of the 250 patients had no right-
heart catheter data in the registry (28%). Of the
remaining 179 patients, 119 (66%) had vasoreac-
tivity testing. A first analysis gave 38% of respon-
ders, which appeared much higher than reported
in the literature. So right heart catheter data were
verified in the source document in 118 of 250 pa-
tients. Of these 118 patients, 31 patients did not
have a right-heart catheter, and 16 had a catheter
but no vasoreactivity testing. In the remaining 71
patients, vasoreactivity was verified according to
the criteria described above. New analysis gave an
overall responder rate of 20% (table 2). Patients
with IPAH were significantly more likely to re-
spond to vasoreactivity testing than were patients
with other aetiologies for PH (p = 0.03). 
In 2004 we estimated the prevalence of PH of
any aetiology in Switzerland at about 25 patients
per one million adult inhabitants. For PAH preva-
lence was 15.5 patients, and for IPAH 8.6 patients
per one million adult inhabitants respectively.
The incidence of PAH was estimated to have in-
creased from 1.2 patients per one million adult in-
habitants in 1999 to 3.5 patients per one million
adult inhabitants in 2004. Respective data for
IPAH were 0.8 patients per one million adult in-
habitants in 1999 and 1.2 patients per one million
adult inhabitants in 2004.
Twenty-four patients (10%) were lost to fol-
low-up. Of the remaining 226 patients, 58 (26%)
died, 7 (3%) had pulmonary thrombendarterec-
tomy (TEA) for CTEPH, 10 (4%) underwent
lung transplantation, 1 patient had liver trans-
plantation, and 150 patients (66%) survived with-
out TEA or transplantation. Median time be-
tween diagnosis and death was 23.5 months,
range 4–196 months. Characteristics of patients
who survived without TEA or transplantation
(“survivors”) and patients who died are shown in
Table 3. Survival as a function of different base-
line parameters is shown in figure 2. 
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Figure 1
Age distribution 
of patients with PH 
in Switzerland. The
black bars show ret-
rospective data from
1991–1999 (from [5]),
prospective data
from 1999–2004 
are in white.
<30 30–39 40–49 50–59 60–69 >70
Age category (years)
% 35
30
25
20
15
10
5
0
Characteristics Total IPAH CTEPH CVD
N = 250 N = 70 N = 73 N = 41
Sex (%) Male 41 36 45 24
Female 59 64 55 76
Age (%) <50 y 32 34 16 29
>50 y 68 66 84 71
NYHA (%) I 1 0 0 5
II 12 10 14 15
III 62 70 57 54
IV 25 20 29 26
n 242 69 73 39
6MWD (m) 367 [246–450] 360 [278–428] 389 [270–450] 383 [229–450]
n 215 64 64 31
Mean pulmonary artery pressure (mm Hg) 47 [37–57] 51 [40–64] 46 [37–56] 43 [34–51]
n 176 58 50 27
Pulmonary vascular resistance (dyn.s.cm–5) 780 [480–1100] 850 [550–1180] 730 [570–1020] 570 [410–910]
n 159 50 48 23
Mixed venous oxygen saturation (%) 61 [54–67] 62 [57–68] 59 [53–63] 61 [49–69]
n 148 48 44 18
Cardiac output (l/min) 3.9 [3.2–5.0] 4.0 [3.3–5.2] 3.6 [3.0–4.2] 4.1 [3.0–5.3]
n 151 47 47 19
Tricuspid regurgitation pressure gradient (mm Hg) 65 [55–80] 70 [56–84] 70 [56–86] 56 [48–65]
n 189 56 51 33
Responder in vasoreactivity testing (%) 20 35 8 20
n 71 20 24 5
Baseline characteristics of patients included in the Swiss Pulmonary Hypertension Registry. For continuous data median and 
[interquartile range] are shown. 
Not shown are following aetiologies (number of patients): PAH associated with congenital shunts (10), with portal hypertension (1), 
with HIV (10), with drugs (3), PAH not further specified (17), pulmonary veno-occlusive disease (1), PH associated with hypoxemia 
or lung disease (18), PH associated with miscellaneous diseases (6). 
IPAH = idiopathic PAH; CTEPH = chronic thrombo-embolic PH; CVD = PAH associated with collagen vascular disease
Table 2
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Figure 2
Survival as a function
of prognostically im-
portant baseline pa-
rameters. 
Survived Died
N = 150 N = 58
Aetiology IPAH 30% 26%
CTEPH 31% 24%
CVD 14% 21%
other 25% 29%
NYHA class III or IV 86% 98%
Male gender 38% 41%
Responder in vasoreactivity testing 23% 20%
6-minute walking distance (m) 400 [300–459] (134) 273 [174–415] (49)
Systolic blood pressure (mm Hg) 124 [110–139] (148) 120 [110–140] (54)
Mean pulmonary artery pressure (mm Hg) 47 [36–57] (107) 51 [39–55] (37)
Systolic pulmonary artery pressure (mm Hg) 74 [59–90] (101) 79 [63–103] (34)
Pulmonary vascular resistance (dyn.s.cm–5) 690 [460–1080] (96) 890 [570–1220] (31)
Cardiac Output (l/min) 4.0 [3.4–5.1] (92) 3.3 [3–5.3] (29)
Mixed venous oxygen saturation (%) 63 [57–68] (88) 56 [50–61] (31) 
Right atrial pressure (mm Hg) 7 [4–11] (81) 11 [4–18] (31)
Tricuspid pressure gradient (mm Hg) 62 [54–80] (116) 69 [57–82] (42)
Age at diagnosis (y) 59 [44–69] (150) 60 [44–70] (58)
Baseline characteristics of patients who survived without transplantation or thrombend-
arterectomy and patients who died during follow-up. For continuous data, median and 
[interquartile range] (sample size) are shown.
Table 3
Discussion
Analysis of the Swiss Registry for Pulmonary
Hypertension yields an estimation of prevalence
and incidence of this disease in Switzerland and
gives some insights in the clinical characteristics
of patients with PH. However, the registry has
some limitations. Although comprehensive infor-
mation has been provided to potential referring
physicians all over Switzerland we cannot assume
that every patient diagnosed with PH in Switzer-
land is included in the registry. Further, it is likely
that patients with functional class I and II are
under-represented probably in part because they
are under-diagnosed. Moreover, the assessment of
patients with PH in the different participating
centres is not identical, and the completeness of
data entered into the register varies. 
The conservative estimates of the prevalence
of PAH and IPAH in Switzerland in 2004 based
on our registry are within the range of the data
from the French Network on Pulmonary Arterial
Hypertension with an estimated prevalence of 15
and 5.9 cases respectively per one million adult 
inhabitants [11]. Both the French and Swiss re -
gistries show a lower prevalence of this disease
than the recently published data from the Scottish
population [26]. Peacock and co-workers found a
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prevalence of PAH of 26 and of IPAH of 9 per
million populations, based on data from the Scot-
tish Pulmonary Vascular Unit. Their data from
the national hospitalisation registry showed even
higher values (52 and 25 per million, respectively).
The conservatively estimated incidence of PAH
in Switzerland in 2004 is in the range of the esti-
mation based on the French registry (2.4 cases per
one million adult inhabitants) [11], but again
lower than the estimated incidence of 7.1 per mil-
lion in the Scottish population [26]. Further stud-
ies from other countries have yet to show which
estimates of prevalence and incidence are closest
to reality, and whether regional differences play a
role. Compared to retrospective data from 1991
to 1999 on PH in Switzerland, the proportion of
patients >50 years of age (68%) is now much
higher (figure 1) [5]. The reason for this might be
the availability of several effective treatments for
this disease [1–3] and the increasing clinical expe-
rience with those treatments. Physicians therefore
consider this disease more often as a potential ex-
planation for exercise intolerance also in elderly
patients. The age shift is also due to the higher
percentage of patients in the registry with
CTEPH (29%) or hypoxaemia-related PH (7%)
than documented in the past (15% and 0% re-
spectively) [5]. The increase in the number of pa-
tients diagnosed with CTEPH may have been
due to a major awareness following the publica-
tion of a study showing a more frequent than ex-
pected development of PH after acute pulmonary
embolism [14]. 
Our patients are still detected at an advanced
stage of the disease, with a mean pulmonary ar-
tery pressure of 50 mm Hg and 87% of patients
having NYHA class III or IV dyspnoea at diagno-
sis. Reasons for this late detection might still be
an insufficient awareness of the disease and the
under-use of echocardiography and diffusion ca-
pacity measurements in the workup of patients
with unexplained dyspnoea. It is also the hallmark
of the disease itself, which progresses insidiously
without specific clinical signs or symptoms until
late, when right heart failure and severe distur-
bance of gas exchange is present. 
Overall mortality over 5 years’ follow-up of
patients with PH of any aetiology included into
the Swiss registry between 1999 and 2004 was
26%. There is no gender difference in mortality.
In this study 6MWD, NYHA class, right atrial
pressure and mixed venous saturation seem to be
important prognostic parameters. There are
other studies, including the retrospective data
from 1991–1999 from the Swiss Registry for Pul-
monary Hypertension [5] confirming the impor-
tance of central venous saturation [10], NYHA
functional class [9, 13], right atrial pressure [9, 15]
and 6-minute walking distance [12] as prognostic
parameters. Pulmonary vascular resistance is nei-
ther a predictor of mortality in this study nor in
others [5, 12]. In contrast to other publications,
parameters like mean pulmonary artery pressure,
cardiac index, or response to vasoreactivity testing
(15–18) could not be identified as significant out-
come parameters. Other parameters shown to
have prognostic importance such as the presence
and size of pericardial effusion on echocardiogra-
phy [19], blood tests such as plasma brain natri-
uretic peptide (20), serum cardiac troponin T [21]
or hyperuricaemia [22] and quality of life assess-
ments [23] were not routinely collected in this
registry. 
The lack of prognostic significance of vasore-
activity testing might be due to the small number
of patients who had vasoreactivity testing with
verified response according to the Venice criteria
(n = 71), with only 20 patients having idiopathic
pulmonary arterial hypertension. The overall va-
soreactivity rate of 20% is in accordance with
other data in the literature [24]. However, right
heart catheterisation and vasoreactivity testing re-
main a weak point of the routine assessment of
patients with PH in Switzerland. Twenty-eight
percent of patients did not undergo right heart
catheterisation, and only 71% of patients who had
right heart catheterisation for diagnosis had va-
soreactivity testing. Whether this is a reporting
bias or reflects reality is not known. It could be ar-
gued that in patients with CTEPH or PH due to
hypoxaemia vasoreactivity, testing is not necessary,
as the prognostic value of this manoeuvre has
been validated only in patients with pulmonary
arterial hypertension. However, vasoreactivity
testing was performed in only 57% of patients
with idiopathic pulmonary arterial hypertension,
but in 44% of patients with CTEPH and 50% of
patients with PH due to hypoxaemia or chronic
lung disease. The significance of positive vasore-
activity test in the latter patients is not yet clear,
but the registry might help to assess this point in
the future – provided that right heart catheterisa-
tion and vasoreacitivity testing are consequently
performed in every patient. As age and co-mor-
bidities of patients with PH increase, the assess-
ment of PH by right heart catheterisation is
strongly recommended. It is the only method that
reliably excludes left heart insufficiency as a rea-
son for the elevated pulmonary artery pressure;
moreover it may correct falsely elevated pressure
gradients measured by echocardiography in pa-
tients with COPD [25].  
In conclusion, the Swiss Registry for Pul-
monary Hypertension is a useful and informative
tool for clinicians involved in the management of
patients with this disease and provides data on
epidemiology of PH patients that compares well
with data from other registries. A high reporting
rate is crucial to have reliable information from
the registry and to improve our epidemiological
understanding of this disease. It may soon be im-
portant to identify patients at an earlier stage of
disease to intervene earlier with new therapies. A
sustained collaboration between general practi-
tioners and specialised PH centres is necessary in
this regard. The management of these patients in
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specialised centres guarantees a high quality of
care, and the regular analysis of the registry data
could be an instrument for quality control and
might help identify weak points in assessment and
treatment of patients affected with a disease lead-
ing to marked disabilities and still high mortality. 
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